Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

  • This share is currently suspended. It was suspended at a price of 42.50

Share Price Information for Beximco Pharma (BXP)

Share Price is delayed by 15 minutes
Get Live Data
42.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £189.60m
BXP Live PriceLast checked at - London Stock Exchange

Intraday Beximco Pharma Share Chart

AGM Notification

19 Nov 2024 07:00

RNS Number : 6600M
Beximco Pharmaceuticals Ltd
19 November 2024
 

19 November 2024

 

BEXIMCO PHARMACEUTICALS LIMITED

 

AGM Notification

 

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that the forty-eighth Annual General Meeting of Shareholders (AGM) of Beximco Pharma will be held on Sunday, the 29th December, 2024 at 10.30 am Bangladesh time under the Virtual Platform through https://bxpharma.bdvirtualagm.com to transact the following business:

 

AGENDA

 

ORDINARY BUSINESS:

 

1. To receive, consider and adopt the Audited Financial Statements of the Company for the year ended on 30th June, 2024 together with reports of the Auditors and the Directors thereon.

2. To declare 40% cash dividend as recommended by the Board of Directors.

3. To elect Directors.

4. To approve the appointment of Managing Director.

5. To approve the re-appointment of Independent Director.

6. To appoint Statutory Auditors for the year 2024-25 and to fix their remuneration.

7. To appoint Corporate Governance Compliance Auditors for the year 2024-25 and to fix their remuneration.

 

SPECIAL BUSINESS:

 

To pass Special Resolutions to change the name of the Company from "Beximco Pharmaceuticals Limited" to "Beximco Pharmaceuticals PLC" as per the provision of the Companies Act, 1994 (as amended in 2020) and to effect the change of the name in the relevant Clauses of the Memorandum and Articles of Association of the Company.

 

The draft of the Special Resolutions proposed to be passed is given below:

 

"Resolved that the name of the Company be changed from Beximco Pharmaceuticals Limited to Beximco Pharmaceuticals PLC and the new name of the Company be incorporated in the Memorandum and Articles of Association of the Company and an amended copy of the Memorandum and Articles of Association of the Company be and is hereby adopted and the same be filed with the Registrar of Joint Stock Companies, Dhaka, Bangladesh for record."

 

Dated: November 18, 2024

By order of the Board,

Sd/-

(MOHAMMAD ASAD ULLAH, FCS)

EXECUTIVE DIRECTOR & COMPANY SECRETARY

 

 

NOTES:

(1) The Shareholders whose names appear in the Share Register of the Company or in the Depository Register on the record date i.e. 25 November, 2024 will be entitled to receive the dividend and to attend the Annual General Meeting.

 

(2) A Member entitled to attend and vote at the General Meeting may appoint a Proxy to attend and vote in his/her stead. The Proxy Form, duly stamped, must be deposited at the Share Department of the Company at BEL Tower, Level-2, 19 Dhanmondi, Road No.1, Dhaka-1205, no later than 48 hours before the time fixed for the meeting.

 

(3) Annual Report for the year 2023-24 will be sent through e-mail address of the valued Shareholders and will be available in the Website of the Company at: www.beximcopharma.com.

 

(4) The valued Shareholders will join the Virtual AGM through the Link https://bxpharma.bdvirtualagm.com. The Shareholders will be able to submit their questions/comments and vote electronically 24 (Twenty-four) hours before commencement of the AGM and also during the AGM. For logging into the system, the Shareholders need to put their 16-digit Beneficial Owner (BO) ID/Folio Number and other credential as proof by visiting the said Link.

 

(5) We encourage the Shareholders to login into the system prior to the meeting. Please allow ample time to login and establish your connectivity. For any IT related guidance, Shareholders may contact vide email : monir@beximco.net or mazibur@beximco.net.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAUWVORSKUAAAA
Date   Source Headline
23rd Nov 20207:00 amRNSNotice of AGM
16th Nov 20207:00 amRNSResults for First Quarter Ended 30 September 2020
13th Nov 20207:00 amRNSResults for First Quarter Ended 30 September 2020
11th Nov 20207:00 amRNSResults for the year ended 30 June 2020
5th Nov 20204:40 pmRNSSecond Price Monitoring Extn
5th Nov 20204:35 pmRNSPrice Monitoring Extension
5th Nov 20202:40 pmRNSMOU with SII and GOB for COVID-19 vaccine
29th Oct 20207:00 amRNSNotification of Preliminary Results and AGM
21st Sep 20207:00 amRNSBeximco Pharma receives eighth FDA approval
28th Aug 202011:06 amRNSSecond Price Monitoring Extn
28th Aug 202011:00 amRNSPrice Monitoring Extension
28th Aug 20208:31 amRNSBeximco and SII to cooperate on a COVID-19 vaccine
30th Jul 20207:00 amRNSBoard Change
23rd Jun 20207:00 amRNSQ3 Financial Results and Business Update
21st May 20207:00 amRNSWorld’s first generic remdesivir for COVID-19
4th May 20207:00 amRNSCOVID-19 Update
30th Mar 20207:00 amRNSBeximco donates PPE to healthcare professionals
24th Feb 20207:00 amRNSBeximco announces Commercial Agreement with Mylan
29th Jan 20207:00 amRNSHalf Year Results 2019-20
20th Jan 202011:06 amRNSPayment of Cash Dividend
23rd Dec 201910:46 amRNSAGM Statement
19th Nov 20198:57 amRNSAGM Notification
14th Nov 20197:00 amRNSResults for First Quarter Ended 30 September 2019
11th Nov 20197:00 amRNSResults for the 12 month period ended 30 June 2019
29th Oct 20197:00 amRNSNotification of Preliminary Results and AGM
8th Aug 20199:18 amRNSUpdate on Dividend and Tax legislation changes
30th Jul 20197:00 amRNSBeximco launches fifth product in the US market
18th Jul 20194:01 pmRNSDividend and Tax changes for Bangladesh companies
29th Apr 20197:00 amRNS3rd Quarter Results
24th Apr 20197:00 amRNSBeximco receives FDA approval for Cyproheptadine
20th Feb 20197:00 amRNSBeximco Pharma to Acquire Eight ANDAs from Sandoz
4th Feb 201911:32 amRNSAppointment of Broker
31st Jan 20197:00 amRNSHalf Year Results 2018-19
22nd Jan 20197:00 amRNSPayment of Cash Dividend
27th Dec 20187:00 amRNSAGM Statement
27th Dec 20187:00 amRNSEGM Statement
30th Nov 20187:00 amRNSEGM Notification
30th Nov 20187:00 amRNSAGM Notification
29th Nov 20188:30 amRNSBeximco Pharma wins at Scrip Awards 2018
14th Nov 20187:00 amRNSResults for First Quarter Ended 30 September 2018
7th Nov 20187:00 amRNSResults for the 12 month period ended 30 June 2018
26th Oct 20187:00 amRNSNotification of Preliminary Results and AGM
30th Jul 20187:00 amRNSUS FDA Approves Beximco Pharma's Nadolol Tablets
23rd Jul 20187:00 amRNSCommences export of fourth product to the US
27th Apr 20187:00 amRNS3rd Quarter Results
23rd Apr 20187:00 amRNSCommences Export of Third Product to the US Market
3rd Apr 20187:00 amRNSCompletion of the Acquisition of Nuvista Pharma
30th Jan 20187:00 amRNSHalf Year Results 2017-18
19th Jan 20187:00 amRNSPayment of Cash Dividend
19th Jan 20187:00 amRNSAcquisition of a Majority Stake in Nuvista Pharma

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.